Navigation Links
Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex

t from second-line treatment with dasatinib".

Data from this publication support ChemGenex’s two-pronged phase 2/3 clinical approach for Ceflatonin, targeting Gleevec-resistant CML patients who harbour the T315I mutation, as well as CML patients who have failed two tyrosine kinase inhibitors (usually Gleevec and Sprycel).

Gleevec®/Glivec® is a registered trademark of Novartis AG.

Sprycel® is a registered trademark of the Bristol-Myers Squibb Company.

Ceflatonin® is a registered trademark of ChemGenex Pharmaceuticals Limited.

About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)

ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex harnesses the power of genomics for target discovery and validation, and in clinical trials to develop more individualized therapeutic outcomes. ChemGenex’s lead compound, Ceflatonin®, is currently in phase 2/3 clinical trials for chronic myeloid leukemia (CML) and Quinamed® is in phase 2 clinical development for prostate, breast and ovarian cancers. The company has a significant portfolio of anti-cancer, diabetes, obesity and depression programs, several of which have been partnered with international pharmaceutical companies. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" and on NASDAQ under the symbol "CXSP".

Contacts

Dr. Greg Collier (CEO and Managing Director) Australia +61 3 5227 2752

USA +1 650 474 9800 ext 103

Dr. Dennis Brown (President and Director) USA +1 650 474 9800 ext 108

Australia +61 3 5227 2703

Safe Harbor Statement

Certain statements made he
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
9. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
Post Your Comments:
(Date:5/15/2008)...Results Confirm Efficacy for Population Most Affec...if., May 16 /-,Bayer Health...s, Inc.,(Nasdaq: ONXX ) today announced that Nexa...overall survival by 47.3 percent (HR=0.68;,p-value...h advanced,hepatocellular carcinoma (HCC), or prim...
(Date:5/15/2008)...RANCISCO, May 15 /- Medivat...ta from an ongoing Phase 1-2 clinical,trial of its... be presented,in an oral presentation at the 44th ...l Meeting in Chicago., Session title: New Targe...Session date and time: Monday, June 2 at 11:30 a.m...
(Date:5/15/2008)...I Data Presented at ASCO Showed Acceptable Tolerab...rade 3 and 4 Neuropathy, WOODCLIFF LAKE, N.J., Ma...apeutic agent eribulin mesylate (E7389) demonstrat...women with locally advanced or metastatic,breast c...e II clinical,trial. The study also suggests that ...
(Date:5/15/2008)...WORTH, N.J., May 15 /- Sche... advancing the science and treatment of,chronic he...hat data from,several clinical studies with PEGINT...bavirin, USP) combination therapy, as well as boce...tease inhibitor, will be presented at,the 39th ann...
Breaking Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Ocera Therapeutics Announces Positive Results with AST 120 in Pouchitis 1265 1Ocera Therapeutics Announces Positive Results with AST 120 in Pouchitis 1265 2Ocera Therapeutics Announces Positive Results with AST 120 in Pouchitis 1265 3Genetic approach provides new insight into trastuzumab resistance in breast cancer 3688 1Genetic approach provides new insight into trastuzumab resistance in breast cancer 3688 2THA Honors Nine Legislators for Contributions to Health Care 3684 1THA Honors Nine Legislators for Contributions to Health Care 3684 2Clubhouse of Suffolk to Host 15th Annual Mental Illness Awareness Day 3680 1Clubhouse of Suffolk to Host 15th Annual Mental Illness Awareness Day 3680 2
... analysis of Phase 2 comparative study showed sign...if, CAMBRIDGE, Mass. and WAYNE, N.J., May 02, 2007... Bayer HealthCare,Pharmaceutical today announced d...study. This interim analysis of all patient data,t...of the study for,all patients showed that a once-y...
...G, Germany, May 03, 2007 /PRNewswire/ -- At the Ap...which provide a sound,scientific basis for a new d...ents. , Tumor tissue-derived primary cell lines ar...ng. During their clonal selection and,expansion, h...,change significantly, thereby losing many of thei...
Other Medicine Technology:Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 2Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 3Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 4Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 5Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 6Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 7Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 8Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 9Indivumed Study Provides Sound Scientific Basis for a Predictive,Drug Test- Platform 2
(Date:5/17/2008)...t report could not establish safe-limit price as g..., May 17 (HealthDay News) -- Those inexpensive ear...y be good for your wallet but bad for your ears an... earrings sold for less than $50 by local San Fran... cause dermatitis on the earlobes and repeated exp...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)... Contract Covers More than 500 Workers, WASHINGT...0 paramedics,and emergency medical technicians in ...gton area have ratified their first-ever contract ...ese workers are now covered by a,strong contract t...ent,future," said Teamsters General President Jim ...
(Date:5/16/2008)...Small fibroids located just beneath the lining of ... the endometrial cavity after uterine artery embol...ations, according to a new study. , The study i...t an MRI examination before and after UAE. The stu...e, 33% migrated to the endometrial cavity after UA...
Breaking Medicine News(10 mins):Health News:Cheaper Earrings More Likely to Contain Nickel 2Health News:Cheaper Earrings More Likely to Contain Nickel 3
... the AMA Rural Reference Group (AMARRG), Dr David ...y Transport Minister, Warren Truss, //of enhanceme...) was a welcome piece of rare good news for rural ...igned to attract GPs to work in country areas and ...
...xperts at University of Iowa are taking efforts to...cribed only when really needed.// Salmeterol is a...on with a corticosteroid, which is inhaled. The us...iorate the asthma for a few people with that condi...
...ers have uncovered important information about how... a critical step in DNA mutation that has eluded r...rs in the August edition of the Journal of the Ame... Institute of Technology have reported uncovering ...
...e about three severe, potentially fatal genetic di...that they can rupture in pregnancy and labor or ev...a blockers, curbing exercise, proactive blood vess...be helpful, but their usefulness varies according ...
Other Medicine News:Health News:RMIF Boost a Boon for Rural Health 2Health News:Salmeterol - to be used in combination & only when required 2Health News:Salmeterol - to be used in combination & only when required 3Health News:Elusive Step In DNA Mutation Uncovered By Researchers 2Health News:Elusive Step In DNA Mutation Uncovered By Researchers 3Health News:Elusive Step In DNA Mutation Uncovered By Researchers 4Health News:Scientists Review Loeys-Dietz Syndrome in the Largest Ever Study to date 2Health News:Scientists Review Loeys-Dietz Syndrome in the Largest Ever Study to date 3
For use with 8 channel pipets.
...sign, manually adjustable dispensing head, and dis...e brings unparalleled flexibility and cost-efficie...t instrument of its kind to offer fast dispensing ...,000L). It also offers the added benefit of being ...
...atented non-contact dispensing technique that coup...valve and stage stepper motor. synQUAD dispenses a...lides, plates, or membranes. At 100 nL dispense vo...less than 10%. An 8-channel synQUAD system dispens...
The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods.
Medicine Products: